obesity

News

Novo Nordisk nears EU approval of obesity drug Wegovy

Danish drugmaker Novo Nordisk is hoping to launch its once-weekly injectable treatment for obesity, Wegovy, in the EU next year after getting a green light from the EMA's human medicines co

News

Regeneron, AZ team up on drugs for obesity "superpower" gene

AstraZeneca has formed a partnership with Regeneron to investigate the potential of treating obesity using drugs directed at GPR75, a protective gene identified by scientists at the Regener

News

FDA ends 7-year obesity drug drought, clearing Novo Nordisk'...

Novo Nordisk is celebrating the FDA approval of its GLP-1 agonist semaglutide as a treatment for obesity, which it believes has the potential to redefine the market for weight-loss medicine

News

Novo Nordisk’s semaglutide effective against obesity in new ...

Novo Nordisk’s hopes of getting semaglutide approved for obesity management may have received a boost, with a new, large trial showing the drug was able to cut body weight significantly over the

News

Price cut leads NICE to back Novo Nordisk’s obesity drug Sax...

Novo Nordisk’s Saxenda has been recommended by NICE as a treatment for obesity, ending a 10-year drought in new drug therapies for weight management.

News

Merck & Co to repurpose failed obesity drug for NASH

Merck & Co is to pay $10 million to Hanmi to repurpose an obesity drug discarded by Johnson & Johnson, into a therapy for the fatty liver disease known as NASH.

Novo Nordisk nears EU approval of obesity drug Wegovy

Regeneron, AZ team up on drugs for obesity "superpower" gene

FDA ends 7-year obesity drug drought, clearing Novo Nordisk'...

Novo Nordisk’s semaglutide effective against obesity in new ...

Price cut leads NICE to back Novo Nordisk’s obesity drug Sax...

Merck & Co to repurpose failed obesity drug for NASH

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

obesity

Editor's Picks